MASH
1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Novo NordiskBAGSVAERD DENMARK, Denmark
1 programGlobal Research Initiative for Patients Screening on MASHN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
2029
2030
2031
Sagimet BiosciencesDenifanstat
Novo NordiskGlobal Research Initiative for Patients Screening on MASH
Clinical Trials (2)
Total enrollment: 10,000 patients across 2 trials
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Start: Mar 2025Est. completion: Dec 2030
Phase 3Withdrawn
Global Research Initiative for Patients Screening on MASH
Start: Jun 2023Est. completion: Mar 203110,000 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 10,000 patients
3 companies competing in this space